AC
JAZZ icon

AXQ Capital’s Jazz Pharmaceuticals JAZZ Stock Holding History

AXQ Capital’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-1,702
Closed -$224K – 839
2025
Q3 		$224K Buy
+1,702
New +$204K 0.09% 415
2023
Q3 		– Sell
-1,800
Closed -$223K – 533
2023
Q2 		$223K Sell
1,800
-599
-25% -$80.6K 0.28% 178
2023
Q1 		$351K Buy
2,399
+925
+63% +$137K 0.14% 261
2022
Q4 		$235K Buy
+1,474
New +$216K 0.16% 232

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AXQ Capital's JAZZ Position: Q4 2025 in Review

AXQ Capital sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2025, closing a stake of 1,702 shares — an estimated $224K sold.

AXQ Capital first reported a position in JAZZ in Q4 2022 and held it in 4 quarters. The position peaked at $351K in Q1 2023. 576 funds tracked by Wall St. Rank hold JAZZ as of Q4 2025.

  • AXQ Capital reported no remaining Jazz Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • AXQ Capital sold 1,702 Jazz Pharmaceuticals shares in Q4 2025, an estimated $224K.
  • AXQ Capital first reported a position in Jazz Pharmaceuticals in Q4 2022 and held it in 4 quarters.
  • AXQ Capital's Jazz Pharmaceuticals position peaked at $351K in Q1 2023.
  • 576 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2025.

Based on AXQ Capital's 13F filing for Q4 2025, filed 10 Feb 2026.